Mitochondrial Hexosamine Flux Directly O-GlcNAcylates HSP60 to Disrupt Chaperone Function and Accelerate Proteotoxic Aggregation in Diabetic Aging

Lila Rodriguez· Mar 23, 2026

Mechanism: High glucose increases mitochondrial O-GlcNAcylation of HSP60, impairing its chaperone function and leading to proteotoxic aggregation. Readout: Readout: Inhibiting mitochondrial O-GlcNAcylation rescues HSP60 activity, reduces protein aggregates, and improves heart health and glucose tolerance.

Hypothesis

Chronic elevation of mitochondrial UDP‑GlcNAc flux drives O‑GlcNAcylation of the mitochondrial chaperone HSP60, reducing its ability to refold imported proteins and thereby promoting aggregation of client proteins such as α‑synuclein and misfolded metabolic enzymes in cardiomyocytes and neurons.

Rationale

The hexosamine biosynthetic pathway (HBP) supplies UDP‑GlcNAc that fuels O‑GlcNAc transferase (OGT) activity in the mitochondrial matrix when the pyrimidine nucleotide carrier pnc1 transports UDP‑GlcNAc across the inner membrane [3].
Mitochondrial OGT mislocalization in diabetic hearts correlates with respiratory dysfunction [3].
HSP60 is a matrix‑localized chaperone essential for folding of mitochondrial proteins; its activity is known to be modulated by post‑translational modifications, yet O‑GlcNAcylation of HSP60 has not been reported.
O‑GlcNAc cycling influences α‑synuclein aggregation and autophagy‑lysosome flux [4], linking HBP flux to proteostasis failure.
Aging activates HBP genes and promotes extracellular matrix GAG accumulation, suggesting a feed‑forward loop where increased flux exacerbates protein aggregation [6].

Mechanistic Insight

We propose that O‑GlcNAcylation of HSP60 occurs on serine/threonine residues within its apical domain, sterically hindering ATP binding and substrate interaction. This modification would shift HSP60 from a high‑affinity folding state to a low‑affinity state, causing accumulation of unfolded client proteins. Aggregated clients could seed cytosolic aggregates (e.g., α‑synuclein) via mitochondria‑associated membranes, providing a direct link between mitochondrial HBP flux and cytosolic proteotoxicity.

Testable Predictions

Detection – Mitochondrial extracts from diabetic mouse hearts or human induced pluripotent stem cell‑derived cardiomyocytes will show increased O‑GlcNAc on HSP60 detectable by immunoprecipitation followed by anti‑O‑GlcNAc Western blot [1].
Functional Consequence – O‑GlcNAcylated HSP60 will exhibit reduced ATPase activity and diminished refolding of a model substrate (e.g., malate dehydrogenase) in vitro.
Genetic Rescue – Cardiac‑specific knockdown of pnc1 or overexpression of mitochondrial‑targeted OGA will decrease HSP60 O‑GlcNAcylation, restore chaperone activity, and reduce mitochondrial protein aggregation measured by filter‑trap assay.
Phenotypic Rescue – Mice with mitochondrial‑restricted OGA overexpression fed a high‑fat diet will preserve ejection fraction, lower cytosolic α‑synuclein oligomers, and exhibit improved glucose tolerance compared with controls.
Pharmacological Test – Acute treatment with the GFAT inhibitor azaserine will lower mitochondrial UDP‑GlcNAc levels and prevent HSP60 O‑GlcNAcylation without affecting cytosolic O‑GlcNAc pools.

Experimental Approach

Model Systems: db/db mice, aged wild‑type mice, and hiPSC‑derived cardiomyocytes/neurons exposed to high glucose (25 mM) for 7 days.
Biochemistry: Mitochondrial isolation, O‑GlcNAc enrichment (click‑chemistry or immuno‑precipitation), HSP60 IP, Western blot for O‑GlcNAc (RL2 antibody). Use mass spectrometry to map modified sites.
Chaperone Assay: Recombinant HSP60 purified from OGT‑overexpressing mitochondria; measure ATP hydrolysis (malachite green) and refolding of chemically denatured MDH.
Aggregation Read‑outs: Filter‑trap for insoluble mitochondrial proteins; immunofluorescence for α‑synuclein puncta; Seahorse respirometry for OXPHOS.
Interventions: AAV9‑mediated cardiac‑specific pnc1 shRNA or mitochondrial OGA (OGA‑MTS); azaserine (50 mg/kg i.p.) or glucosamine (2 g/L drinking water) as controls.
Readouts: Echocardiography, blood glucose, insulin tolerance test, behavioral assays for motor coordination (if neuronal model).

Potential Outcomes and Falsification

If O‑GlcNAcylation of HSP60 is not elevated in diabetic mitochondria, or if altering its modification does not change chaperone activity or aggregation levels, the hypothesis would be falsified. Conversely, confirming the predictions would support a model where mitochondrial HBP flux directly sabotages proteostasis via chaperone modification, offering a target distinct from systemic glucose lowering for preventing diabetic‑age‑related proteinopathies.

References (inline)

[1] https://www.aging-us.com/article/100647/text [2] https://pmc.ncbi.nlm.nih.gov/articles/PMC3985334/ [3] https://doi.org/10.1073/pnas.1424017112 [4] https://pubmed.ncbi.nlm.nih.gov/41146299/ [5] https://doi.org/10.1101/2025.04.30.651461 [6] https://doi.org/10.1101/2023.11.17.567640

Hypothesis

Rationale

The hexosamine biosynthetic pathway (HBP) supplies UDP‑GlcNAc that fuels O‑GlcNAc transferase (OGT) activity in the mitochondrial matrix when the pyrimidine nucleotide carrier pnc1 transports UDP‑GlcNAc across the inner membrane [3].

Mitochondrial OGT mislocalization in diabetic hearts correlates with respiratory dysfunction [3].

HSP60 is a matrix‑localized chaperone essential for folding of mitochondrial proteins; its activity is known to be modulated by post‑translational modifications, yet O‑GlcNAcylation of HSP60 has not been reported.

O‑GlcNAc cycling influences α‑synuclein aggregation and autophagy‑lysosome flux [4], linking HBP flux to proteostasis failure.

Aging activates HBP genes and promotes extracellular matrix GAG accumulation, suggesting a feed‑forward loop where increased flux exacerbates protein aggregation [6].

Mechanistic Insight

Testable Predictions

Detection – Mitochondrial extracts from diabetic mouse hearts or human induced pluripotent stem cell‑derived cardiomyocytes will show increased O‑GlcNAc on HSP60 detectable by immunoprecipitation followed by anti‑O‑GlcNAc Western blot [1].

Functional Consequence – O‑GlcNAcylated HSP60 will exhibit reduced ATPase activity and diminished refolding of a model substrate (e.g., malate dehydrogenase) in vitro.

Genetic Rescue – Cardiac‑specific knockdown of pnc1 or overexpression of mitochondrial‑targeted OGA will decrease HSP60 O‑GlcNAcylation, restore chaperone activity, and reduce mitochondrial protein aggregation measured by filter‑trap assay.

Phenotypic Rescue – Mice with mitochondrial‑restricted OGA overexpression fed a high‑fat diet will preserve ejection fraction, lower cytosolic α‑synuclein oligomers, and exhibit improved glucose tolerance compared with controls.

Pharmacological Test – Acute treatment with the GFAT inhibitor azaserine will lower mitochondrial UDP‑GlcNAc levels and prevent HSP60 O‑GlcNAcylation without affecting cytosolic O‑GlcNAc pools.

Experimental Approach

Model Systems: db/db mice, aged wild‑type mice, and hiPSC‑derived cardiomyocytes/neurons exposed to high glucose (25 mM) for 7 days.

Biochemistry: Mitochondrial isolation, O‑GlcNAc enrichment (click‑chemistry or immuno‑precipitation), HSP60 IP, Western blot for O‑GlcNAc (RL2 antibody). Use mass spectrometry to map modified sites.

Chaperone Assay: Recombinant HSP60 purified from OGT‑overexpressing mitochondria; measure ATP hydrolysis (malachite green) and refolding of chemically denatured MDH.

Aggregation Read‑outs: Filter‑trap for insoluble mitochondrial proteins; immunofluorescence for α‑synuclein puncta; Seahorse respirometry for OXPHOS.

Interventions: AAV9‑mediated cardiac‑specific pnc1 shRNA or mitochondrial OGA (OGA‑MTS); azaserine (50 mg/kg i.p.) or glucosamine (2 g/L drinking water) as controls.

Readouts: Echocardiography, blood glucose, insulin tolerance test, behavioral assays for motor coordination (if neuronal model).

Potential Outcomes and Falsification